Vesencumab

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C91728

1205533-60-3

C91728

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

CTRP

GDC

FDA

A human IgG1 monoclonal antibody directed against neuropilin-1 (NRP1), with potential antiangiogenic and antineoplastic activities. Upon intravenous administration, vesencumab specifically targets and binds to NRP1; the antibody-NRP1 complex prevents the subsequent coupling of NRP1 to VEGFR2, thereby potentially inhibiting VEGF-mediated signaling and potentially preventing angiogenesis. In combination with other anti-VEGF therapies, vesencumab may enhance their anti-angiogenic effect. NRP1 is a membrane-bound co-receptor normally expressed by endothelial cells and overexpressed by certain tumor cells, and plays a role in angiogenesis, cell survival, migration, and invasion.

Vesencumab

7SF22186WT

Vesencumab

MNRP-1685A

MNRP1685A

VESENCUMAB

Immunoglobulin GL, Anti-(Human Neuropilin 1) (Human Monoclonal MNRP1685a Heavy Chain), Disulfide with Human Monoclonal MNRP1685a Light Chain, Dimer

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C33981

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

Vesencumab

Vesencumab

Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A

614996

614996

614996

Vesencumab

Thesaurus:C91728

Vesencumab

Pharmacologic Substance

Amino Acid, Peptide, or Protein

C2984519

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129822

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C20401

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1742